Nes-Ziona, Israel, Nov 13, 2017 – Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that Dr. Clifford S. Deutachman has joined its Organ Failure – Sepsis clinical advisory board.
Dr. Deutschman is a graduate of Trinity College (BS), Northwestern University (MS) and New York Medical College (MD). After flirtations with surgery and neurosurgery he completed training in surgical critical care (Univ of Minnesota) and Anesthesiology (Johns Hopkins). He was on the faculty at Johns Hopkins (1988-1993) and Penn (1993-2014) as a specialist in Critical (Intensive) Care Medicine. As a member of Penn’s Department of Anesthesiology and Critical Care, he directed the Fellowship in Critical Care Medicine, the NIH-funded Research Fellowship (T32) and the Stavropoulos Sepsis Research Program. He joined Northwell Health as vice chairman of research for the Department of Pediatrics in 2014. Dr. Deutschman has served as president of the Society of Critical Care Medicine in 2012, and the American Society of Critical Care Anesthesiologists from 2002 to 2004. He has been a permanent member of the NIH Surgery, Anesthesia and Trauma Study Section. He is scientific editor of the journal, Critical Care Medicine, and serves on the editorial boards of a number of other journals. He has been the recipient of a number of awards and honors including the Lifetime Achievement Award from the Society of Critical Care Anesthesiologists. Dr Deutschman’s research focuses on sepsis, a common, life-threatening disorder that arises when the body’s response to infection injures its’ own tissues and organs, a topic on which he is achieved international recognition. He is one of the co-authors of the most recent version of Surviving Sepsis Campaign Guidelines and is currently co-chair of an international task force to re-examine and refine the definitions of sepsis. Dr. Deutschman has co-authored over 100 peer-reviewed publications and over 80 book chapters and editorials. He is the co-editor of the textbook Evidence-Based Practice of Critical Care
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g. Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. For more information, visit http://www.enlivex.com.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.